Today: 29 April 2026
Browse Category

NASDAQ:FEMY 16 October 2025 - 3 November 2025

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys shares jumped as much as 25% pre-market Nov. 3 after the company won FDA approval to begin the final phase of its FemBloc pivotal trial and secured up to $58 million in new financing. FEMY closed up 8% at $0.69 after hitting $0.79 intraday. FemBloc recently gained CE Mark and approvals in the UK and New Zealand. Q2 sales rose 85% to $0.41 million, with a net loss of $4.59 million.
3 November 2025
·
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys Inc. shares surged 46% intraday on Oct. 16, 2025, closing up 35% at $0.745 amid heavy trading. The rally followed news of regulatory approvals for its FemBloc® birth control system in Europe, UK, and New Zealand, and a major order from a Spanish distributor. The company also announced new partnerships and showcased its fertility treatments at an industry conference. Femasys remains unprofitable but reported 85% year-over-year sales growth in Q2.
17 October 2025
··
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (NASDAQ: FEMY) jumped 46% to $0.80 by mid-day Oct. 16 after announcing its FemaSeed fertility treatment will be showcased at ASRM 2025. The company recently secured European, UK, and New Zealand approvals for its FemBloc birth control device and reported its first European sales and new distribution deals. Q2 revenue rose 85% year-over-year to $0.409 million.
16 October 2025
··

Stock Market Today

  • British American Tobacco Shares Appear Undervalued Despite 45% One-Year Rally
    April 29, 2026, 10:46 AM EDT. British American Tobacco (LSE:BATS) has surged 45.3% over the past year, sparking debate on whether it remains a good buy. The stock currently trades at £43.12, up 4.9% in the last week but slightly down 0.9% over 30 days. Analysts and Simply Wall St's Discounted Cash Flow (DCF) model project future cash flows boosting intrinsic value to £67.05 per share, suggesting a 35.7% undervaluation. The tobacco giant scored 5 out of 6 on Simply Wall St's valuation framework, underscoring potential appeal to income-focused investors chasing dividends and stability. While the recent price growth is notable, the DCF analysis indicates room for further upside, challenging perceptions that the easy gains have been fully priced in.

Latest article

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

29 April 2026
Enphase Energy shares dropped 7.3% to $31.80 after reporting a first-quarter revenue decline to $282.9 million and a GAAP loss of $7.4 million. U.S. revenue fell 23% from the prior quarter, with sell-through demand down 48% sequentially. Adjusted earnings beat estimates, but investors appeared unconvinced demand had stabilized. SolarEdge and Sunrun shares also fell in early trading.
Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

29 April 2026
Western Digital shares rose 9.3% to $427.45 Wednesday after Seagate’s quarterly forecast topped estimates and sent storage stocks higher. Seagate shares jumped 16.6%. Seagate projected fourth-quarter revenue of $3.45 billion and non-GAAP earnings of $5 a share. Western Digital will report fiscal third-quarter results after markets close Thursday.
Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

29 April 2026
Generac Holdings raised its 2026 sales outlook after first-quarter net sales rose 12% and commercial and industrial sales jumped 28% to $510 million, driven by data center demand. Shares climbed 11% after adjusted earnings of $1.80 a share beat estimates. The company now expects full-year net sales growth in the mid-to-high teens percentage range, up from its prior forecast. Generac also increased its adjusted EBITDA margin guidance.
Go toTop